Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023
As a leading provider of state-of-the-art cancer diagnostic technology, Lunit has focused on developing novel AI biomarkers for application in immunotherapy.
- As a leading provider of state-of-the-art cancer diagnostic technology, Lunit has focused on developing novel AI biomarkers for application in immunotherapy.
- This year, Lunit's presentations at ASCO GI 2023 will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict liver and colon cancer treatment outcomes.
- Lunit SCOPE IO assesses a patient's cancer tissue slide image by analyzing the distribution of tumor-infiltrating lymphocytes (TILs)—one of the representative immunocytes that fight cancer cells.
- One of the studies to be presented investigates the correlation between AI-powered immune phenotype and real-world outcomes in liver cancer.